Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon Congleton
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 0.69
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 3.81
Financials
Net Income
$-57.33MEBITDA
$-54.13M-7366.3%Free Cash Flow
$-43.10MEPS (diluted)
$-0.64Shares Outstanding (diluted)
88.99M+1658.7%Operating Expenses
$60.09MCash & Debt
$624.67MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-154.65M | $-2.29 |
| 2024 | $0.00 | $-177.81M | $-3.66 |
| 2023 | $0.00 | $-71.90M | $-1.99 |
| 2022 | $0.00 | $-29.80M | $-5.77 |
| 2021 | $0.00 | $-19.41M | $-3.89 |
| 2020 | $0.00 | $-3.43M | $-0.74 |
Valuation
MLYShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
45-10.00%Social Signal Score
Mentions (16)
- Newsglobenewswire.com·14d ago·Neutral
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 – In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline –
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
…s Slow ASI Ramp (Upgrade) Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise, restrictive payer policies, and step therapy barriers, limiting near-term market penetration. Peak sales for lorundrostat are modeled at ~$800 million, but the current valuation appears fair; I upgrade from 'Sell' to 'Hold' given the risk/reward balance.
View source ↗ - Newsmarketbeat.com·18d ago·Negative
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call Mineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for Dec. 22, executives said on the company's third-quarter earnings call.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…r 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026 RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter…
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International - Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
View source ↗ - Newsglobenewswire.com·31d ago·Negative
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
…s Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been app…
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 - New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
…w Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrost…
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
…ys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2…
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
…te-Breaking Presentation at American Heart Association Scientific Sessions 2026 RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety da…
View source ↗ - Newsseekingalpha.com·80d ago·Positive
… to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with Baxfendy, MLYS's focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction.
View source ↗ - Newsglobenewswire.com·88d ago·Neutral
…Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fa…
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Negative
Mineralys Therapeutics Q2 Earnings Call Highlights Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.65 per share
Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.64 vs $-0.55miss
- Wed, Aug 12$-2.85 vs $-0.55miss
- Wed, May 6$-0.47 vs $-0.51beat
- Thu, Mar 12$-0.40 vs $-0.52beat
- Mon, Nov 10$-0.52 vs $-0.66beat
- Tue, Aug 12$-0.66 vs $-0.78beat
Estimates and results for MLYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MLYS officers and directors.
- Bought
- $8.8m
- Sold
- $15.6m
2 trades
33 trades
- Congleton Jonsold
- Slingsby Brian Taylorsold
- Warren Ericsold
- Karydas Daphnesold
- Warren Ericsold
- Rodman David Malcomsold
- Warren Ericsold
- Rodman David Malcomsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MLYS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
